Multigene panels in prostate cancer risk assessment: A systematic review

Genetics in Medicine

Volumn 18, Issue 6, 2016, Pages 535-544

  Little, Julian ^a   Wilson, Brenda ^a   Carter, Ron ^b   Walker, Kate ^b   Santaguida, Pasqualina ^b   Tomiak, Eva ^c   Beyene, Joseph ^b   Usman Ali, Muhammad ^b   Raina, Parminder ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

genetic susceptibility to disease; genetic testing; prostate cancer; risk assessment; systematic review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; ALLELE; AUTOPSY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; DIGITAL RECTAL EXAMINATION; ECONOMIC ASPECT; FAMILY HISTORY; GENE FREQUENCY; GENETIC RISK; GENETIC SCREENING; GENOMICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HISPANIC; HUMAN; MALE; NEWCASTLE OTTAWA SCALE; PREDICTION; PROACTIVE GENOMICS; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY ASSESSMENT OF DIAGNOSTIC ACCURACY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM BASED PANEL; SYSTEMATIC REVIEW; TUMOR BIOPSY; VALIDITY; GENETICS; PATHOPHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR;

BIOMARKERS, TUMOR; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84975045654     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.125     Document Type: Review

References (96)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
3. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics (2014). Canadian Cancer Society: Toronto, ON, 2014
4. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101: 1280-1283
5. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-1721
6. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: a systematic review and metaanalysis. Int J Cancer 2008; 123: 430-435
7. Grönberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-864
8. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000; 343: 78-85
9. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802
10. Cuzick J, Fisher G, Kattan MW, et al.; Transatlantic Prostate Group. Long-Term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95: 1186-1194
11. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-Three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995; 172: 65-72
12. Bill-Axelson A, Holmberg L, Ruutu M, et al.; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984
13. Donovan J, Hamdy F, Neal D, et al.; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88
14. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009; 30: 81-87
15. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329
16. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-Analysis of randomised controlled trials. BMJ 2010; 341: c4543
17. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011; 107: 882-891
18. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134
19. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014; 311: 1143-1149
20. Bell N, Connor GS, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014; 186: 1225-1234
21. Al Olama AA, Kote-Jarai Z, Berndt SI, et al.; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; COGS (Collaborative Oncological Gene-environment Study) Consortium; GAME-ON/ELLIPSE Consortium. A meta-Analysis of 87, 040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46: 1103-1109
22. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001; 357: 709-712
23. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 2003; 72: 636-649
24. Haddow J, Palomaki G. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press: New York, 2003: 217-233
25. Little J, Wilson BJ, Carter R, et al. Multi-Gene Panels in Prostate Cancer Risk Assessment. Evidence Report No. 209 (prepared by the McMaster University Evidence-based Practice Center under contract no. HHSA2902007-10060-1). Agency for Healthcare Research and Quality: Rockville, MD, 2012. AHRQ Publication No.12-E020-EF
26. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews (prepublication draft copy). AHRQ Publication No. 10(11)-EHC063-EF. Agency for Healthcare Research and Quality: Rockville, MD, 2011
27. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309
28. Hindorff LA, MacArthur J, Wise A, et al. A Catalog of Published Genome-wide Association Studies. 2011. www.genome.gov/gwastudies
29. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14
30. Wells G, Shea B, O'Connel D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quailty of nonrandomised studies in meta-Analyses. 1 February 2009
31. Whiting PF, Rutjes AW, Westwood ME, et al.; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536
32. Sterne JAC, Egger M. Regression methods to detect publication and other bias in meta-Analysis. In: Rothstein HR, Sutton AJ, Borenstein M, eds. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments. John Wiley & Sons Chester, UK, 2005: 99-110
33. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol 2011; 64: 1277-1282
34. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-919
35. Salinas CA, Koopmeiners JS, Kwon EM, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69: 363-372
36. Sun J, Chang BL, Isaacs SD, et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008; 68: 1257-1262
37. Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, Catalona WJ. Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol 2010; 184: 501-505
38. Zheng SL, Sun J, Wiklund F, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009; 15: 1105-1111
39. Xu J, Sun J, Kader AK, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-1572
40. Sun J, Lange EM, Isaacs SD, et al. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate 2008; 68: 489-497
41. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009; 15: 1787-1793
42. Beuten J, Gelfond JA, Franke JL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1869-1880
43. Penney KL, Salinas CA, Pomerantz M, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009; 15: 3223-3230
44. Sun J, Kader AK, Hsu FC, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2011; 71: 421-430
45. Helfand BT, Kan D, Modi P, Catalona WJ. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a normal prostate specific antigen and digital rectal examination. Prostate 2011; 71: 394-402
46. Aly M, Wiklund F, Xu J, et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol 2011; 60: 21-28
47. Wiklund FE, Adami HO, Zheng SL, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009; 18: 1659-1662
48. Lindström S, Schumacher FR, Cox D, et al. Common genetic variants in prostate cancer risk prediction-results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2012; 21: 437-444
49. Chen SH, Ip EH, Xu J, Sun J, Hsu FC. Using graded response model for the prediction of prostate cancer risk. Hum Genet 2012; 131: 1327-1336
50. Zheng J, Liu F, Lin X, et al. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-Associated SNPs. Prostate 2012; 72: 577-583
51. Kader AK, Sun J, Reck BH, et al. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol 2012; 62: 953-961
52. Sun J, Na R, Hsu FC, et al. Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history. Eur Urol 2013; 63: 585-587
53. Agalliu I, Wang Z, Wang T, et al. Characterization of SNPs associated with prostate cancer in men of Ashkenazic descent from the set of GWAS identified SNPs: impact of cancer family history and cumulative SNP risk prediction. PLoS One 2013; 8: e60083
54. Akamatsu S, Takahashi A, Takata R, et al. Reproducibility, performance and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One 2012; 7: e46454
55. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727-1731
56. Xu J, Zheng L, Gronberg H, Isaac W. Methods and compositions for correlating genetic markers with prostate cancer risk. [US 2009/0226912A1]. 10 September 2009. United States Patent Application Publication. 19 December 2008
57. Zheng L, Xu J, Trent J, Bleecker E, Turner A. Proactive Genomics. 2008
58. Newcombe PJ, Reck BH, Sun J, et al. A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol 2012; 36: 71-83
59. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-1844
60. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151-1158
61. Shao N, Jiang WY, Qiao D, et al. An updated meta-Analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies. Cancer Biomark 2012; 12: 37-47
62. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935
63. Eng J. Receiver operating characteristic analysis: a primer. Acad Radiol 2005; 12: 909-916
64. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, Kasamesup V, Thakkinstian A. Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 2012; 133: 1-10
65. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302: 2345-2352
66. deCODEme. http://www.decodeme.com/complete-genetic-scan. 8 June 2011. 18 July 2011
67. Gudmundsson J, Sulem P. Genetic variants contributing to risk of prostate cancer. http://www.freepatentsonline.com/20110020320.pdf. US 2011/0020320A1. 27 January 2011. United States Patent Application Publication. 8 May 2009
68. Kalf RR, Mihaescu R, Kundu S, de Knijff P, Green RC, Janssens AC. Variations in predicted risks in personal genome testing for common complex diseases. Genet Med 2014; 16: 85-91
69. 23andMe. 2015. https: //customercare.23andme.com
70. 23andMe Health Reports. 2015. Canada: https: //www.23andme.com/en-ca/; UK: https: //www.23andme.com/en-gb/; Europe: https: //www.23andme.com/en-eu/health/
71. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-138
72. Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol 2010; 37: 31-38
73. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-674
74. Burke W, Burton H, Hall AE, et al.; Ickworth Group. Extending the reach of public health genomics: what should be the agenda for public health in an era of genome-based and personalized medicine Genet Med 2010; 12: 785-791
75. Doukas DJ, Li Y. Men's values-based factors on prostate cancer risk genetic testing: a telephone survey. BMC Med Genet 2004; 5: 28
76. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004; 291: 71-78
77. Cowan R, Meiser B, Giles GG, Lindeman GJ, Gaff CL. The beliefs and reported and intended behaviors of unaffected men in response to their family history of prostate cancer. Genet Med 2008; 10: 430-438
78. Catalona WJ, D'Amico AV, Fitzgibbons WF, et al. What the US Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012; 157: 137-138
79. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostatespecific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30: 3020-3025
80. Payton S. Prostate cancer: new PSA screening guideline faces widespread opposition. Nat Rev Urol 2012; 9: 351
81. Witte JS. Personalized prostate cancer screening: improving PSA tests with genomic information. Sci Transl Med 2010; 2: 62ps55
82. Scardino PT. Prostate cancer: improving PSA testing by adjusting for genetic background. Nat Rev Urol 2013; 10: 190-192
83. Weinberg DS, Myers RE, Keenan E, et al. Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: a randomized trial. Ann Intern Med 2014; 161: 537-545
84. Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151: 878-885
85. Palomaki GE, Melillo S, Neveux L, et al. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies-A targeted evidence-based review. Genet Med 2010; 12: 772-784
86. Vickers AJ, Lilja H. Predicting prostate cancer many years before diagnosis: how and why? World J Urol 2012; 30: 131-135
87. Wilt TJ, Brawer MK, Jones KM, et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
88. Holmberg L, Bill-Axelson A, Helgesen F, et al.; Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-789
89. Johansson E, Steineck G, Holmberg L, et al.; SPCG-4 Investigators. Long-Term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011; 12: 891-899
90. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-448
91. Lane JA, Donovan JL, Davis M, et al.; ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014; 15: 1109-1118
92. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005; 97: 1043-1055
93. Macinnis RJ, Antoniou AC, Eeles RA, et al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol 2011; 35: 549-556
94. Machiela MJ, Chen CY, Chen C, Chanock SJ, Hunter DJ, Kraft P. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol 2011; 35: 506-514
95. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 1321-1330
96. Kane RL, Guise J, Hartman K, Rothenberg B, Trikalinos T, Wilt T. Presentation of Future Research Needs. 9. 2012. Agency for Healthcare Research and Quality. Methods Future Research Needs Report. 27 June 2012